Coronary heart disease benefits from blood pressure and lipid-lowering

International Journal of Cardiology

Volumn 135, Issue 2, 2009, Pages 218-222

  Sever, Peter S ^a   Poulter, Neil R ^a   Mastorantonakis, Stylianos ^a   Chang, Choon Lan ^a   Dahlof, Bjorn ^b   Wedel, Hans ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

Author keywords

Blood pressure; CHD events; Lipid lowering

Indexed keywords

AMLODIPINE; ANTILIPEMIC AGENT; ATENOLOL; ATORVASTATIN; CHOLESTEROL; PERINDOPRIL; THIAZIDE DIURETIC AGENT;

ALGORITHM; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; TREATMENT RESPONSE;

AMLODIPINE; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD PRESSURE; CORONARY DISEASE; HEPTANOIC ACIDS; HUMANS; HYPERTENSION; PERINDOPRIL; PYRROLES; RISK FACTORS; RISK REDUCTION BEHAVIOR; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 67349278469     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2009.01.036     Document Type: Article

References (26)

1. Sever P.S., Dahlöf B.A., Poulter N.R., et al., for the ASCOT Investigators. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens 19 (2001) 1139-1147
2. Dahlöf B., Sever P.S., Poulter N.R., et al., for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 (2005) 895-906
3. Sever P.S., Dahlöf B., Poulter N.R., et al., for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
4. Poulter N.R., Wedel H., Dahlöf B., et al., for the ASCOT Investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 366 (2005) 907-913
5. Sever P.S., and Poulter N.R. Blood pressure reduction is not the only determinant of outcome. Circulation 113 (2006) 2754-2763
6. Elliott W.J., Jonsson M.C., and Black H.R. It is not beyond the blood pressure; it is the blood pressure. Circulation 113 (2006) 2763-2774
7. Messerli F.H., Williams B., and Ritz E. Essential hypertension. Lancet 370 (2007) 591-603
8. Wang C.Y., Liu P.Y., and Liao J.K. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 14 (2008) 37-44
9. Collins R., and Peto R. Antihypertensive drug therapy: effects on stroke and coronary heart disease. In: Swales J.D. (Ed). Text book of hypertension (1994), Blackwell Scientific Publications, Oxford 1156-1164
10. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362 (2003) 1527-1535
11. Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
12. MacMahon S. Blood pressure and the risks of cardiovascular disease. In: Swales J.D. (Ed). Textbook of hypertension (1994), Blackwell Scientific Publications, Oxford 46-57
13. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R., and Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002) 1903-1913
14. Anderson K.M., Wilson P.W., Odell P.M., and Kannel W.B. An updated coronary risk profile. A statement for health professionals. Circulation 83 (1991) 356-362
15. Sever P.S., Poulter N.R., Dahlof B., Wedel H., and for the Anglo-Scandinavian Trial Investigators. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes trial-Lipid-lowering Arm. Am J Cardiol 96 (2005) 39F-44F [suppl]
16. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 291 (1985) 97-104
17. Coope J., and Warrender T.S. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 293 (1986) 1145-1151
18. Medical Research Council Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 304 (1992) 405-412
19. The Treatment of Mild Hypertension Research Group. The Treatment of Mild Hypertension Study. A randomised, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Arch Intern Med 151 (1991) 1413-1423
20. Sever P., Dahlöf B., Poulter N., et al., for the ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 24 (2006) 2982-2988
21. Haq I.U., Ramsay L.E., Yeo W.W., Jackson P.R., and Wallis E.J. Is the Framingham risk function valid for north European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart 18 1 (1999) 114-115
22. D'Agostino R.B., Vasan R.S., Pencina M.J., Wolf M.C., Massaro J.M., and Kannel W.B. General cardiovascular risk profile for use in primary care; the Framingham Heart Study. Circulation 117 (2008) 743-753
23. Sever P.S., Poulter N.P., Dahlof B., Wedel H., and for the Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-lowering Arm (ASCOT-LLA). Am J Cardiol 96 (2005) 39F-44F [suppl]
24. Conroy R.M., Pyörälä K., Fitzgerald A.P., et al., SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24 11 (2003) 987-1003
25. Wolf-Maier K., Cooper R.S., Kramer H., et al. Hypertension treatment and control in five European countries, Canada and the United States. Hypertension 43 (2004) 10-17
26. Coats A.J. Ethical authorship and publishing. Int J Cardiol 131 (2009) 149-150